Sunday, Nov. 22, 2026 A Vik Media Group publication
Mongevity Longevity in Motion
Leer en español

A new pancreatic cancer vaccine did best in people whose bodies responded strongly

Pancreatic cancerPart of a story we are following · 4 articles · See every update
Personal trainer assisting a woman with a balance exercise on grass in an outdoor park.
Personal trainer assisting a woman with a balance exercise on grass in an outdoor park.Photo: PTPioneer / Wikimedia Commons, CC BY 2.0

If you or someone you love has been through treatment for pancreatic cancer, here is something worth knowing. Researchers are building a vaccine that teaches the body’s own defenses to hunt for the cancer, and they just learned who it seems to help most.

In a study of people treated for stage I to III pancreatic cancer, 96 who received the vaccine camupepimut and 48 who got standard care or observation, the vaccine was as safe as observation, and those whose immune systems responded strongly stayed free of cancer much longer. The vaccine did not meet its main goal across the whole group, but the signals point researchers toward a clearer next step.

How the study worked

This was a randomized phase 2 trial called AMPLIFY-7P. It enrolled people with stage I to III pancreatic cancer that carried a KRAS gene mutation, who had no return of cancer within 6 months of standard treatment. By chance, 96 received the vaccine and 48 got standard care or observation. The results were published on Oct. 23, 2026, in Nature Medicine. The main result was not statistically significant, and the most encouraging findings came from further analyses, so a larger trial needs to confirm them.

What they found

Over the whole group, the time before cancer returned was about 24 months with the vaccine (23.8 months) and about 21 months without it (21.2 months). That gap was too small to count as a clear win.

But look at the 6-month mark. About 76% of vaccinated people (75.7%) were still cancer-free, compared with about 62% (61.7%) of the others.

The vaccine works by training T cells, a type of immune cell, to spot the mutated KRAS protein found in most pancreatic tumors. And it did that. Nearly everyone who got it, 98.9% (89 of 90 people tested), developed T cells aimed at the mutation.

Here is the standout. In 82.2% of vaccinated people (74 of 90), the immune response grew more than 9.17 times above where it started. Among them, the typical time without cancer returning had not been reached yet by the end of the analysis. For those with a smaller response, it was 6.08 months. Researchers measured this as a much lower chance of relapse for strong responders (a hazard ratio of 0.22).

Two other groups looked especially good. People with no tumor DNA detectable in their blood, and people who had not had radiation before, did better with the vaccine.

Safety was reassuring. Serious side effects happened in 10.4% of vaccinated people (10 of 96) and 14.6% of those on standard care or observation (7 of 48).

Why do immune responses matter here?

Think of the vaccine as a training session for your body’s security team. When the team learns the target well, it can catch cancer cells that slipped past surgery and chemotherapy. The finding that a strong response went along with longer time cancer-free tells researchers the idea is working in the people whose bodies take it up well. That helps them plan a bigger phase 3 trial.

What you can do today

If someone close to you has finished pancreatic cancer treatment, sit down together and write out three questions for the next oncology visit: what follow-up tests are planned, whether a blood test for tumor DNA makes sense, and which clinical trials might fit. You can also search for trials yourself on ClinicalTrials.gov, which lists this vaccine study.

Got a question? Ask us ›

Get the best of longevity science by emailThe most useful new studies, in plain language and with the source. Free.

We'll email you once to confirm. Occasional messages from our sponsors, clearly labeled. Unsubscribe anytime. We never ask for health data.
Cite this article
AMA
Mongevity Desk. A new pancreatic cancer vaccine did best in people whose bodies responded strongly. Mongevity. Published November 9, 2026. Accessed November 22, 2026. https://mongevity.science/cancer/2026/11/pancreatic-cancer-vaccine-camupepimut-immune-response/
Vancouver
Mongevity Desk. A new pancreatic cancer vaccine did best in people whose bodies responded strongly [Internet]. Mongevity; 2026 Nov 9 cited 2026 Nov 22]. Available from: https://mongevity.science/cancer/2026/11/pancreatic-cancer-vaccine-camupepimut-immune-response/
APA
Mongevity Desk. (2026, November 9). A new pancreatic cancer vaccine did best in people whose bodies responded strongly. Mongevity. https://mongevity.science/cancer/2026/11/pancreatic-cancer-vaccine-camupepimut-immune-response/
For your website
<a href="https://mongevity.science/cancer/2026/11/pancreatic-cancer-vaccine-camupepimut-immune-response/">A new pancreatic cancer vaccine did best in people whose bodies responded strongly</a>

Free to share or quote with credit and a link.

Questions and answers

What is camupepimut?
It is a vaccine that trains T cells, a type of immune cell, to recognize mutated KRAS, a gene change found in most pancreatic tumors.
Did the vaccine work in the trial?
Not across the whole group. The time before cancer returned was 23.8 months with the vaccine and 21.2 months without. People with strong immune responses did much better.
Was the vaccine safe?
Yes. Serious side effects were no more common than with observation: 10.4% with the vaccine and 14.6% without.
What happens next?
The researchers plan a refined phase 3 trial to confirm the signals seen in this study.

Sources

  1. Nature Medicine, AMPLIFY-7P randomized phase 2 trial of the mKRAS vaccine camupepimut in pancreatic cancer (PMID 42919966 · DOI 10.1038/s41591-026-04734-7) · 2026-11-02
  2. Trial registration NCT05726864 · 2026-11-02

More on this story

Report an error